Chitosan tellrium nanoparticles and method of manufacturing the same

Chitosan tellurium nanoparticles are synthesized through a specific method involving potassium tellurite and low molecular weight chitosan, addressing the lack of effective Te NP applications by providing stable and functional nanoparticles for biomedical uses with antibacterial, antifungal, and antioxidant properties.

KR103047805B1Active Publication Date: 2026-11-11KNU IND COOPERATION FOUND
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020240007393
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-01-17
Publication Date
2026-11-11
Estimated Expiration
2044-01-17

AI Technical Summary

Technical Problem

There is a lack of comprehensive understanding and effective utilization of tellurium nanoparticles (Te NPs) in biomedical applications due to their potential toxicity and limited research on biopolymer-capped Te NPs, particularly in conjunction with chitosan, which could enhance their physicochemical and biological properties.

Method used

The synthesis of chitosan tellurium nanoparticles (CS-Te NPs) is achieved by conjugating potassium tellurite with low molecular weight chitosan, involving steps such as preparing potassium tellurite and chitosan solutions, mixing, precipitate formation, centrifugation, and freeze-drying to produce stable and functional nanoparticles.

Benefits of technology

The resulting CS-Te NPs exhibit multifunctional properties suitable for biomedical applications, demonstrating antibacterial, antifungal, antioxidant, and cytotoxic effects, with potential for drug delivery and other biomedical uses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024006357225-PAT00001_ABST
    Figure 112024006357225-PAT00001_ABST
Patent Text Reader

Abstract

The present invention relates to chitosan tellurium nanoparticles and a method for manufacturing the same, wherein nanoparticles are produced by conjugating potassium tellurite and low molecular weight chitosan so that they can be applied as multifunctional materials for biomedical applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to chitosan tellurium nanoparticles and a method for manufacturing the same, and more specifically, to chitosan tellurium nanoparticles and a method for manufacturing the same, which are produced by conjugating potassium tellurite and low molecular weight chitosan to enable them to be applied as multifunctional materials for biomedical applications. Background Technology

[0002] Chitosan (CS), a unique cationic biopolymer, contains amino and hydroxyl functionalities that facilitate numerous applications by tuning its physicochemical properties (crystallization, solubility, viscosity, and biodegradability). These physicochemical properties depend primarily on the molecular weight range and degree of deacetylation of CS. With advantages in antimicrobial, biodegradable, hemostatic, mucosal adhesion, pH responsiveness, cytocompatibility, and biocompatibility properties, CS serves as a potential drug delivery molecule in various application fields (antimicrobials, antifungals, anti-inflammatory agents, anticancer agents, antivirals, antioxidants, osteoporosis, etc.). CS has ensured stability, long-term blood circulation, cell permeability, and pH-responsive delivery of drug molecules. Furthermore, the biocompatibility of metal nanoparticles (gold (Au), iron (Fe), silver (Ag), copper (Cu), zinc (zn), etc.) can be enhanced by encapsulating or functionalizing them with CS. Additionally, CS can control the size and shape of metal NPs. In general, metal NPs represent potent biomedical and environmental applications. However, most metal NPs are unstable and exhibit higher toxicity. Therefore, metal nanoparticles utilizing biopolymers (cellulose, starch, chitosan, lignin, etc.) have been fabricated with enhanced physicochemical and biological properties.

[0003] Among metal-polymer combinations, CS is considered an important macromolecule as its use in combination with various metal NPs increases. CS-metal combinations have demonstrated synergistic effects in various cases, such as reducing toxicity. Few metal NPs possess potential activity for diverse applications, and most do not exhibit diverse activities due to their physicochemical properties. Furthermore, due to toxicity, most activities and properties have not been well studied in all aspects. Among them, tellurium (Te) is a metal that has not been extensively studied recently, yet it has been found to be utilized in energy storage, solar cells, and microbial inhibition. Due to the potential toxicity of tellurium to mammalian systems, further research on Te and Te-based materials in biotechnological and biomedical applications is gradually decreasing.

[0004] Tellurium is a metalloid element (atomic number 52 and atomic mass 127.6) that exists in various forms and oxidation states. Te oxyanions are highly toxic to microorganisms, and in particular, TeO32-(+4) is more toxic than TeO42-(+6). More importantly, the toxicity to pathogens is as follows. Therefore, the synthesis of Te nanomaterials with tunable properties can be useful for plants, animals, and the environment. However, biopolymer-capped Te NPs have not been sufficiently studied in the available literature to be understood. Consequently, there is a growing need for technologies that embody this.

[0005] Accordingly, in the present invention, CS-based Te NPs were synthesized and their physicochemical properties were verified, and antibacterial, antifungal, antibiometabolic, antioxidant, and cytotoxic properties were evaluated. Prior art literature

[0006] Korean Patent Publication No. 10-2023-0135305 (Published September 25, 2023), "Chitosan-encapsulated iron nanoparticles derived from Trichoderma harzianum and method for manufacturing the same" The problem to be solved

[0007] In order to solve the above-mentioned problems, the present invention aims to provide chitosan tellurium nanoparticles and a method for manufacturing the same, which can be applied as multifunctional materials for biomedical applications by manufacturing nanoparticles through the conjugation of potassium tellurite and low molecular weight chitosan. means of solving the problem

[0008] To achieve the above objectives, the present invention comprises: a potassium tellurite solution preparation step (S10) of preparing a potassium tellurite solution by dissolving potassium tellurite (K2TeO3) in distilled water; a chitosan solution preparation step (S20) of preparing a chitosan solution by dissolving low molecular weight chitosan in an acetic acid solution; a mixing step (S30) of preparing a mixture by adding the chitosan solution prepared in the chitosan solution preparation step (S20) to the potassium tellurite solution prepared in the potassium tellurite solution preparation step (S10); a precipitate formation step (S40) of forming a precipitate by stirring the mixture from the mixing step (S30); and a collection step (S50) of collecting chitosan tellurium nanoparticles (CS-Te NPs) by centrifuging the precipitate formed in the precipitate formation step (S40). The present invention provides a method for manufacturing chitosan tellurium nanoparticles, characterized by including a freeze-drying step (S60) in which the chitosan tellurium nanoparticles (CS-Te NPs) collected in the collection step (S50) are washed with distilled water and freeze-dried.

[0009] At this time, the potassium tellurite solution in the potassium tellurite solution preparation step (S10) is characterized by being prepared by dissolving potassium tellurite (K2TeO3; MW 253.79 g / mol) in distilled water to a concentration of 10 mM.

[0010] At this time, the chitosan solution in the chitosan solution preparation step (S20) is characterized by being prepared by dissolving low molecular weight chitosan, which has a molecular weight of 50-190 kDa, a degree of deacetylation (DDA) of 75-80%, and a viscosity of 20-300 cP, in a 0.1-1.0% acetic acid solution to a concentration of 2 mg / mL.

[0011] At this time, the mixture in the mixing step (S30) is characterized by being prepared by adding the chitosan solution prepared in the chitosan solution preparation step (S20) to the potassium tellurite solution prepared in the potassium tellurite solution preparation step (S10) in a volume ratio of 1000 to 200.

[0012] At this time, the precipitate in the precipitate formation step (S40) is characterized by being formed by stirring the mixture of the mixing step (S30) at a temperature of 5 to 45°C for 20 to 40 minutes.

[0013] At this time, the chitosan tellurium nanoparticles (CS-Te NPs) in the collection step (S50) are collected by centrifuging the precipitate formed in the precipitate formation step (S40) at a speed of 10,000 to 14,000 rpm for 10 to 20 minutes.

[0014] In addition, the present invention provides chitosan tellurium nanoparticles (CS-Te NPs) characterized by adding a chitosan solution, prepared by dissolving low molecular weight chitosan in an acetic acid solution, to a potassium tellurite solution prepared by dissolving potassium tellurite (K2TeO3) in distilled water, stirring the mixture to form a precipitate, collecting the precipitate by centrifugation, washing with distilled water, and freeze-drying.

[0015] At this time, the potassium tellurite solution is characterized by being prepared by dissolving potassium tellurite (K2TeO3; MW 253.79 g / mol) in distilled water to a concentration of 10 mM.

[0016] At this time, the chitosan solution is characterized by being prepared by dissolving low molecular weight chitosan, which has a molecular weight of 50-190 kDa, a degree of deacetylation (DDA) of 75-80%, and a viscosity of 20-300 cP, in a 0.1-1.0% acetic acid solution to a concentration of 2 mg / mL.

[0017] At this time, the above mixture is characterized by being prepared by adding a chitosan solution to the potassium tellurite solution in a volume ratio of 1000:200.

[0018] At this time, the precipitate is characterized by being formed by stirring the mixture at a temperature of 5 to 45°C for 20 to 40 minutes.

[0019] At this time, the chitosan tellurium nanoparticles (CS-Te NPs) are collected by centrifuging the precipitate at a speed of 10,000 to 14,000 rpm for 10 to 20 minutes. Effects of the invention

[0020] The chitosan tellurium nanoparticles according to the manufacturing method of the present invention can be applied as multifunctional materials for biomedical applications by manufacturing nanoparticles through the conjugation of potassium tellurite and low molecular weight chitosan. Brief explanation of the drawing

[0021] FIG. 1 shows TEM micrographs of CS-Te NPs at different magnifications (a), (b), (c); elemental mapping images (d), (e), (f), (g); and an elemental spectrum graph (h). FIG. 2 is a graph (a) regarding the zeta size analysis of CS-Te NPs; an image (b) regarding the FTIR spectra of CS and CS-Te NPs; an image (c) regarding the XRD spectrum of CS; and an image (d) regarding the XRD spectra of CS-Te NPs (25°C) and CS-Te NPs (200°C). Figure 3 shows XPS analysis images of CS-Te NPs (a), tellurium (b), oxygen (c), nitrogen (d), and carbon (e). Figure 4 is an image regarding the thermogravimetric analysis (TGA) of CS and CS-Te NPs. FIG. 5 shows an image (a) regarding the antimicrobial activity of CS-Te NPs against various bacterial pathogens through well-diffusion analysis; a graph (bf) regarding the various bacterial growth inhibitory properties of CS-Te NPs at different concentrations; and a graph (g) regarding the MIC of CS-Te NPs against various bacterial pathogens. Figure 6 shows images regarding the biofilm inhibition properties of CS-Te NPs, including photographs (a, b) of Gram-positive and Gram-negative bacterial biofilm plates and a bar graph (c) showing the biofilm inhibition rate. Figure 7 shows an image (a) regarding the antifungal activity of CS-Te NPs and graphs (b, c) regarding the DPPH and ABTS radical scavenging ability of CS-Te NPs. Fig. 8 shows a graph of cell viability for CS-Te NPs on NIH3T3 cells and A549 cells (ab); and cell staining analysis images of CS-Te NP-treated A549 cells (c, d). Fig. 9 shows a graph of cell viability for PC3 cells treated with CS-Te NPs (a); and cell staining analysis images of PC3 cells treated with CS-Te NPs (b, c). Figure 10 is an image regarding the particle size distribution of CS-Te NPs in a TEM image measured with ImageJ software. Figure 11 is an image regarding the antifungal activity of CS-Te NPs against filamentous fungal pathogens. Specific details for implementing the invention

[0022] The following detailed descriptions relating to the present invention refer to the accompanying drawings, which are embodiments in which the present invention may be practiced and are illustrated as examples of such embodiments. These embodiments are described in detail to sufficiently enable those skilled in the art to practice the present invention. It should be understood that various embodiments of the present invention are different but need not be mutually exclusive. For example, specific shapes, structures, and characteristics described herein may be implemented in different embodiments without departing from the spirit and scope of the present invention in relation to one embodiment. Furthermore, it should be understood that the location or arrangement of individual components within each described embodiment may be changed without departing from the spirit and scope of the present invention.

[0023] Accordingly, the following detailed description is not intended to be taken in a limiting sense, and the scope of the invention is limited only by the appended claims, including all equivalents to those claimed therein, provided they are properly described. Similar reference numerals in the drawings refer to the same or similar functions across various aspects.

[0024] The terms used in this invention have been selected based on currently widely used general terms, taking into account their functions within the invention; however, these terms may vary depending on the intent of those skilled in the art, case law, the emergence of new technologies, etc. Additionally, in specific cases, terms have been arbitrarily selected by the applicant, and in such cases, their meanings will be described in detail in the relevant description of the invention. Therefore, the terms used in this invention should be defined not merely by their names, but based on their meanings and the overall content of the invention.

[0025] In the present invention, when a part is described as “comprising” a certain component, this means that, unless specifically stated otherwise, it does not exclude different components but may include additional different components.

[0027] Hereinafter, the chitosan tellurium nanoparticles according to the present invention and the method for manufacturing the same will be described in detail.

[0029] A method for manufacturing chitosan tellurium nanoparticles according to the present invention comprises: a potassium tellurium solution preparation step (S10) of preparing a potassium tellurium solution by dissolving potassium tellurium (K2TeO3) in distilled water; a chitosan solution preparation step (S20) of preparing a chitosan solution by dissolving low molecular weight chitosan in an acetic acid solution; a mixing step (S30) of preparing a mixture by adding the chitosan solution prepared in the chitosan solution preparation step (S20) to the potassium tellurium solution prepared in the potassium tellurium solution preparation step (S10); a precipitate formation step (S40) of forming a precipitate by stirring the mixture from the mixing step (S30); and a collection step (S50) of collecting chitosan tellurium nanoparticles (CS-Te NPs) by centrifuging the precipitate formed in the precipitate formation step (S40). and is characterized by including a freeze-drying step (S60) in which the chitosan tellurium nanoparticles (CS-Te NPs) collected in the collection step (S50) are washed with distilled water and freeze-dried.

[0031] In the above potassium tellurite solution preparation step (S10), a process of preparing a potassium tellurite solution by dissolving potassium tellurite (K2TeO3) in distilled water is performed.

[0032] More specifically, the potassium tellurite solution in the potassium tellurite solution preparation step (S10) is suitablely prepared by dissolving potassium tellurite (K2TeO3; MW 253.79 g / mol) in distilled water to a concentration of 10 mM.

[0034] In the chitosan solution preparation step (S20) above, a process of preparing a chitosan solution by dissolving low molecular weight chitosan in an acetic acid solution is performed.

[0035] The chitosan solution in the chitosan solution preparation step (S20) above is suitable to be prepared by dissolving low molecular weight chitosan, which has a molecular weight of 50-190 kDa, a degree of deacetylation (DDA) of 75-80%, and a viscosity of 20-300 cP, in a 0.1-1.0% acetic acid solution to a concentration of 2 mg / mL.

[0036] More specifically, the chitosan solution in the chitosan solution preparation step (S20) is suitablely prepared by dissolving low molecular weight chitosan, which has a molecular weight of 50-190 kDa, a degree of deacetylation (DDA) of 75-80%, and a viscosity of 20-300 cP, in a 0.5% acetic acid solution to a concentration of 2 mg / mL.

[0038] In the above mixing step (S30), a process is performed to prepare a mixture by adding the chitosan solution prepared in the chitosan solution preparation step (S20) to the potassium tellurite solution prepared in the above potassium tellurite solution preparation step (S10).

[0039] More specifically, the mixture in the mixing step (S30) is suitablely prepared by adding the chitosan solution prepared in the chitosan solution preparation step (S20) to the potassium tellurite solution prepared in the potassium tellurite solution preparation step (S10) in a volume ratio of 1000 to 200.

[0041] In the above precipitate formation step (S40), the mixture from the above mixing step (S30) is stirred to form a precipitate.

[0042] The precipitate in the above precipitate formation step (S40) is preferably formed by stirring the mixture of the above mixing step (S30) at a temperature of 5 to 45°C for 20 to 40 minutes.

[0043] More specifically, the precipitate in the precipitate formation step (S40) is preferably formed by stirring the mixture of the mixing step (S30) at a temperature of 25°C for 30 minutes.

[0045] In the above collection step (S50), the process of collecting chitosan tellurium nanoparticles (CS-Te NPs) by centrifuging the precipitate formed in the above precipitate formation step (S40) is performed.

[0046] The chitosan tellurium nanoparticles (CS-Te NPs) in the above collection step (S50) are appropriately collected by centrifuging the precipitate formed in the above precipitate formation step (S40) at a speed of 10,000 to 14,000 rpm for 10 to 20 minutes.

[0047] More specifically, the chitosan tellurium nanoparticles (CS-Te NPs) in the collection step (S50) are appropriately collected by centrifuging the precipitate formed in the precipitate formation step (S40) at a speed of 12,000 rpm for 15 minutes.

[0049] In the freeze-drying step (S60), the chitosan tellurium nanoparticles (CS-Te NPs) collected in the collection step (S50) are washed with distilled water and freeze-dried.

[0050] More specifically, in the freeze-drying step (S60), the chitosan tellurium nanoparticles (CS-Te NPs) collected in the collection step (S50) are washed three times with distilled water and freeze-dried at -50℃.

[0052] In addition, the present invention provides chitosan tellurium nanoparticles (CS-Te NPs) characterized by adding a chitosan solution, prepared by dissolving low molecular weight chitosan in an acetic acid solution, to a potassium tellurite solution prepared by dissolving potassium tellurite (K2TeO3) in distilled water, stirring the mixture to form a precipitate, collecting the precipitate by centrifugation, washing with distilled water, and freeze-drying.

[0053] The above potassium tellurite solution is a chitosan tellurium nanoparticle characterized by being prepared by dissolving potassium tellurite (K2TeO3; MW 253.79 g / mol) in distilled water to a concentration of 10 mM.

[0054] Chitosan tellurium nanoparticles (CS-Te NPs), characterized by the above chitosan solution being prepared by dissolving low molecular weight chitosan, having a molecular weight of 50-190 kDa, a degree of deacetylation (DDA) of 75-80%, and a viscosity of 20-300 cP, in a 0.1-1.0% acetic acid solution to a concentration of 2 mg / mL.

[0055] Chitosan tellurium nanoparticles (CS-Te NPs) characterized by the above mixture being prepared by adding a chitosan solution to the potassium tellurite solution in a volume ratio of 1000:200.

[0056] The above precipitate is chitosan tellurium nanoparticles (CS-Te NPs) characterized by being formed by stirring the mixture at a temperature of 5 to 45°C for 20 to 40 minutes.

[0057] It is preferable to collect the above chitosan tellurium nanoparticles (CS-Te NPs) by centrifuging the precipitate at a speed of 10,000 to 14,000 rpm for 10 to 20 minutes, washing them 1 to 5 times with distilled water, and freeze-drying them at -50℃.

[0059] Below, the effects of the chitosan tellurium nanoparticles according to the present invention will be examined in detail through the following examples, comparative examples, and experimental examples.

[0061] 1. Materials and Methods

[0062] 1.1. Materials

[0063] Low molecular weight chitosan (50-190 kDa, 75-80% degree of deacetylation (DDA) and viscosity (20-300 cP)), potassium tellurate (K2TeO3; MW 253.79 g / mol), fluconazole, and tetracycline hydrochloride were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Additionally, fluorescent stains acridin orange, propidium iodide, rhodamine 123, and dichlorofluorescein diacetate were purchased from Sigma-Aldrich (St. Louis, MO, USA). Growth media for antimicrobial assays, such as nutrient medium (NB) and Muller-Hinton liquid medium (MHB), were purchased from MBcell in Seoul, South Korea. Sabouraud Dextrose Broth (SDB), Potato Glucose Agar (PDA), and agar powder were purchased from BD Difco™ of Thermo Fisher Scientific, South Korea. Dulbecco's Modified Eagle Medium (DMEM) (HyClone) was purchased from Cytiva, South Korea. RPMI (Roswell Park Memorial Institute) medium (Gipco) was purchased from Thermo Fisher Scientific, South Korea. The kit (Cellomax™) was purchased from MediFab, South Korea. Solvents including glacial acetic acid, DMSO, and ethanol were purchased from Daejung Chemicals & Metal.

[0065] 1.2. Chitosan Tellurium nanoparticles CS - Te NPs Preparation of )

[0066] The chitosan tellurium nanoparticles (CS-Te NPs) of the example were prepared according to the following process.

[0067] Potassium tellurite solution preparation step (S10): Potassium tellurite (K2TeO3; MW 253.79 g / mol) was dissolved in distilled water to a concentration of 10 mM to prepare a potassium tellurite solution.

[0068] Chitosan solution preparation step (S20): A chitosan solution was prepared by dissolving low molecular weight chitosan, which has a molecular weight of 50-190 kDa, a degree of deacetylation (DDA) of 75-80%, and a viscosity of 20-300 cP, in a 0.5% acetic acid solution to a concentration of 2 mg / mL.

[0069] Mixing step (S30): A mixture was prepared by adding the chitosan solution prepared in the chitosan solution preparation step (S20) to the potassium tellurite solution prepared in the potassium tellurite solution preparation step (S10) in a volume ratio of 1000:200.

[0070] Precipitate formation step (S40): The mixture from the mixing step (S30) was stirred at a temperature of 25°C for 30 minutes to form a precipitate.

[0071] Collection step (S50): The precipitate formed in the precipitate formation step (S40) was centrifuged at a speed of 12,000 rpm for 15 minutes to collect chitosan tellurium nanoparticles (CS-Te NPs).

[0072] Freeze-drying step (S60): The chitosan tellurium nanoparticles (CS-Te NPs) collected in the collection step (S50) are washed three times with distilled water and freeze-dried at -50℃.

[0074] 1.3. Chitosan ( CS Preparation of )

[0075] As a comparative example, low molecular weight chitosan (50-190 kDa, 75-80% degree of deacetylation (DDA) and viscosity (20-300 cP)) was purchased from Sigma-Aldrich (St. Louis, Missouri, USA) and prepared.

[0077] 2.3. CS- Te Confirmation of NP characteristics

[0078] The shape, size, and elemental composition of S-Te NPs were measured by field emission transmission electron microscopy (FE-TEM) (JEOL-JSM 1200EX, Japan). The hydrodynamic particle size distribution of CCS-Te NPs was enumerated using ImageJ software (ImageJ bundled with 64-bit Java 1.8.0_172). The particle size behavior of CS-Te NPs in an aqueous medium was calculated using a particle size analyzer (Malvern PANalytical, Netherlands). The chemical interactions of CS-Te NP fabrication were investigated by Fourier transform infrared spectroscopy (FTIR) (PerkinElmer Paragon 500, USA). Additionally, the crystalline properties of CS and CS-Te NP fabrication were verified by evaluating them through X-ray diffraction analysis (XRD) (X'pert-pro MPD-PANalytical, Netherlands). In addition, the atomic electronic states, chemical bonds, and elemental composition of CS-Te NPs were determined by X-ray photoelectron spectroscopy (XPS) (Thermo Scientific, K Alpha+, UK). Furthermore, the heat resistance properties of CS and CS-Te NPs were evaluated using a thermal analyzer (TA) (DSC Q2000 / SDT Q600, New Castle, DE, USA).

[0080] 2.4. CS - Te Biological applications of NP

[0081] 2.4.1. Microorganisms

[0082] The bacterial pathogens Staphylococcus aureus ATCC 19095, Bacillus cereus ATCC 14579, Listeria monocytogenes ATCC 15313, Salmonella enterica ATCC 14028, and Escherichia coli ATCC 43888 were purchased from KORAM BIOTECH CORP in South Korea. Candida albicans (KCCM11282) was purchased from the Korean Culture Center for Microbiology (KCCM). In addition, the filamentous pathogenic fungi Aspergillus fumigatus (KCTC6145), Aspergillus niger (KCTC6985), and Aspergillus flavus (KCTC6633) were obtained from the Korean Specimen Culture Center (KCTC).

[0083] 2.4.2. Antimicrobial Activity

[0084] The antimicrobial properties of CS-Te NPs were evaluated against bacterial pathogens via well diffusion and liquid medium dilution methods, in accordance with prior reports. Briefly, bacterial pathogens were initially cultured on nutrient agar (NA) medium using the quadrant striation method. Additionally, single colonies were cultured overnight in nutrient broth (NB) medium in a shaking incubator at 37°C. For well diffusion analysis, bacterial pathogens were inoculated onto pre-prepared sterile MHA plates using sterile swab exchange. Wells were prepared in the MHA medium using a sterile steel perforator. To evaluate the antimicrobial efficacy of CS-Te NPs, various concentrations of CS-Te NPs were prepared by dispersing them in sterile distilled water loaded into each well and compared with the standard antibiotic tetracycline hydrochloride. These plates were incubated overnight in a 37°C incubator. The antimicrobial activity of CS-Te NPs was determined by measuring the inhibition zone around the wells. Furthermore, bacterial growth at various concentrations of CS-Te NPs was determined by the liquid medium dilution method. Briefly, 100 μL of MHB medium with serially diluted CS-Te NP concentrations was added to each well. Additionally, 20 μL of bacterial pathogens were inoculated and incubated in an incubator at 37°C for 48 hours. The growth rate of each bacterial strain was evaluated by measuring absorbance at 600 nm at different pre-fixed time intervals. Bacteria inoculated without a sample were considered as a control. The minimum inhibitory concentration (MIC) of CS-Te NP for each bacterium was evaluated by comparison to the control.

[0085] 2.4.3. anti-candidase activity

[0086] The anti-Candidative activity of CS-Te NPs against C. albicans was evaluated using the conventional well diffusion method. First, a suspension culture of C. albicans was developed by incubating it overnight at 37°C in SDB medium. Additionally, wells inoculated with pre-sterilized MHA medium were prepared, and the anti-Candidative activity of CS-Te NPs at various concentrations was evaluated according to the above section (Section 2.4.2). Fluconazole, a standard anti-candidase drug, was used as a positive control for this analysis, and the MIC of CS-Te NPs against C. albicans was evaluated.

[0087] 2.4.4. Antifungal activity

[0088] The antifungal activity of CS-Te NPs against filamentous fungi (A. flavus, A. fumigatus, and A. niger) was evaluated using the well-diffusion method and growth inhibition assays. In summary, filamentous fungi obtained from KCTC were cultured in PDA medium and incubated in an incubator at 28±2°C for 24 hours. After incubation, the fungal suspension was cultured in PDA medium, and wells were developed in the medium to add samples using a sterile metal perforator. Then, 50 μL of CS-Te NPs at various concentrations were added to each well of the plate and incubated for 2–3 days with continuous monitoring. The antifungal activity of CS-Te NPs against filamentous fungi was determined by measuring the inhibition zone around the wells. Additionally, the growth inhibitory properties of CS-Te NPs were evaluated by incubating the filamentous fungal culture suspension with various concentrations of CS-Te NPs for 6 hours. After incubation, a fungal suspension inoculated with 50 μL of CS-Te NPs on PDA was incubated, and growth was compared with that of an untreated sample. Similarly, the MIC of CS-Te NPs against filamentous fungi was determined.

[0089] 2.4.5. Antioxidant Analysis

[0090] The antioxidant efficacy of CS-Te NPs was evaluated by DPPH and ABTS radical scavenging assays. Briefly, 100 μL of serially diluted concentrations of CS-Te NPs were separately added to 100 μL of free radical solutions (DPPH solution (100 μM prepared in methanol) and ABTS solution (7 mM ABTS and 2.45 mM potassium persulfate incubated in the dark). Then, the solution was diluted with ethanol for 10 minutes under dark conditions to fix the optical density of the working solution at 0.7 ± 0.02. Subsequently, the ABTS and DPPH free radical scavenging efficacy of CS-Te NPs was evaluated by measuring optical densities at 517 nm and 734 nm, respectively, and based on this, the percentage of radical scavenging ability of CS-Te NPs was calculated.

[0091] 2.4.6. Cell Viability Analysis

[0092] Cytogenic efficacy of CS-Te NPs evaluated in non-cancerous (NIH3T3) and cancerous cell lines (A549 and PC3) via cell viability analysis and fluorescence staining analysis. Non-cancerous and cancerous cells were cultured, respectively, in T-25 flasks containing FBS and antibiotics in DMEM and RPMI media at 37°C in a 5% CO2 incubator. 90% confluence cells were trypsinized, washed with PBS, and resuspended in their respective media. In the cell viability experiment, 1×10⁶ 4Cells (100 μL) were added to a 96-well plate with serially diluted concentrations of CS-Te NPs, and the plate was incubated in an incubator for 24 hours. Then, 10 microliters of WST cell viability assay solution were added to each well, and the plate was incubated for an additional 1 hour under the aforementioned conditions. After incubation, the absorbance of the 96-well plate was measured at 450 nm using a UV-visible spectrophotometer, and the percentage of cell viability was listed in comparison to the control group. In addition, the behavior of cancer cells treated with CS-Te NPs was evaluated using fluorescence staining assays. Briefly, cells in the apoptotic phase, nuclear damage, reactive oxygen species generation, and mitochondrial membrane potential loss induced by CS-Te treatment were analyzed using a fluorescence microscope with AO / EB double staining, PI staining, DFCH-DA, and Rh123 staining, respectively.

[0093] 2.7. Statistical Analysis

[0094] Experimental results were presented as means with standard deviations. In addition, one-way analysis of variance was used to evaluate statistical significance. A P-value of less than 0.05 was considered statistically significant.

[0096] 3. Results and Discussion

[0097] 3.1. CS - Te Synthesis of NPs

[0098] CS-based metal NPs have been widely developed for advanced applications in medicine, agriculture, food preservation, industry, and environmental improvement. There are various methods for producing CS-processed metal composites, which may vary depending on the purpose. For example, CS-metal NP composites are fabricated in various forms such as nanoparticles, nanorods, hydrogels, films, and nanofibers. Furthermore, functional polymers can reduce metal salts to metal NPs via in situ synthesis methods, and their physical properties (size and shape) can be controlled due to their stabilization and reduction characteristics. In addition, CS can act as an encapsulation / capping agent for metal NPs synthesized extrinsically by other synthesis methods. Due to the steric stabilization of CS, it can exclude van der Waals forces and tightly encapsulate metal NPs through electrostatic interactions. Several types of CS-metal nanocomposites have been reported, demonstrating enhanced functional and biological properties. However, this applies only to Te NPs that have not yet been prepared with CS, and key results have been demonstrated. Therefore, in the present invention, Te NPs prepared from CS were synthesized by direct mixing without using other reducing / stabilizing agents. Meanwhile, the physicochemical and biological properties of CS-Te NPs are discussed in detail below.

[0100] 3.2. CS - Te Characteristics of NP

[0101] 3.2.1. CS - Te NP's TEM analyze

[0102] CS is involved in the synthesis of various metal NPs with or without the presence of Au, Ag, Pt, Cu, ZnO, Pd, and other stabilizers. In this study, Te NPs were synthesized using chitosan (CS) itself without other reducing agents. The morphological and elemental characteristics of CS-mediated synthesized Te NPs observed in FE-TEM (Fig. 1) are shown. The results indicate that the CS-Te NPs are polydisperse and spherical, with dimensions less than 100 nm (Fig. 1a-c). Furthermore, the average particle size of the CS-Te NPs calculated using ImageJ software was 37.48 ± 14.56 dnm (Fig. 10). Additionally, the spherical CS-Te NPs prepared in situ were dispersed within the CS matrix due to electrostatic attraction. Similarly, studies synthesizing lignin-based Te NPs using ultrasound showed that the Te NPs were dispersed within the lignin matrix. More importantly, the aggregation of CS-Te NPs may be due to the drying process during the sample preparation stage. In addition, the presence of tellurium, nitrogen, and carbon was confirmed through EDS layer images and extended individual element mapping images (Figure 1d-g). Likewise, the elemental spectrum also confirmed the presence of C, Te, and N (Figure 1h). These results indicate that CS can have the efficiency to reduce potassium tellurite into CS fabricated Te NPs.

[0103] 3.2.2. Zeta Size Analysis

[0104] The hydrodynamic size and particle surface characteristics of CS-Te NPs in an aqueous medium were studied using a Zeta size analyzer (Fig. 2a). The results indicate that the CS-Te NPs have a hydrodynamic size of 1368 ± 52.08 d·nm, a polydispersity index of 0.288 ± 0.11, and a zeta potential of 7.90 ± 1.86 mV. The hydrodynamic size of the CS-Te NPs was greater than 1 μm, which may be due to aggregation caused by interparticle attraction of positively surface-charged particles. Furthermore, TEM analysis of the freeze-dried CS-Te NPs clearly showed that the nanoparticles were coated and dispersed within the same polymer matrix. Additionally, the CS-Te NPs exhibited a positive zeta potential of 7.90 ± 1.86 mV. CS is a positively charged cationic polymer, and nanomaterials prepared from CS, which exhibits a predominantly positive charge, have been reported elsewhere.

[0105] 3.2.3. FTIR analyze

[0106] The chemical interactions and surface chemical modifications of CS and CS-Te NPs were studied by FTIR spectroscopy (Fig. 2b). The FTIR spectrum of CS was at 3290 cm⁻¹. -1 , 2870cm -1 , 1651cm -1 , 1580cm -1 , 1374cm -1 , 1315cm -1 , 1060cm -1 and 1024cm -1 The main peak was marked at 3290 cm. -1 The moderately broad peak of CS corresponds to OH (intermolecular bonds) and NH stretching. 2870 cm⁻¹ -1 The peak is attributed to CH stretching due to the acetyl group of CS. 1651 cm⁻¹ -1 (amide I) and 1580 cm -1The peaks of (amide II) are attributed to the CO (carbonyl) and NH (amine) stretching, respectively. Additionally, 1374 cm⁻¹ -1 and 1315cm -1 The CS peaks in this sequence could be C-CH3amide and CO-NH amide III formation, respectively. Furthermore, at 1060 cm⁻¹ -1 and 1024cm -1 The peak corresponds to the CH bending of CS. The CS-Te NP is at 3294 cm⁻¹ -1 , 2872cm -1 , 1643cm -1 , 1550cm -1 , 1376cm -1 , 1313cm -1 , 1065cm -1 , 1024cm -1 and 602cm -1 It showed a major peak that is very similar to CS and only slightly shifted (Figure 2b). The peak shift and the formation of a new peak indicate the synthesis of CS-Te NPs.

[0107] 3.2.4. XRD analyze

[0108] The crystallographic properties of CS and CS-fabricated Te NPs were evaluated via XRD analysis (Figs. 2c and d). CS exhibits semicrystalline properties, with peaks appearing at 10.22° and 20.08° (Fig. 2c). These correspond to the amorphous crystalline phases (020) and (110), respectively. Te NPs fabricated from CS were synthesized at room temperature (25°C) and their crystallographic properties were investigated (Fig. 2d). The results showed no significant crystallographic peaks, except for a small peak appearing at 28.52° corresponding to the crystalline phase (101) of Te. This phenomenon caused by CS can hide Te within the polymer matrix and obscure Te signals. Generally, thermal processes can aid in exploring metal NPs in polymer composites by degrading the polymer matrix. To protect sample properties, CS-Te NPs were calcined at 200°C for 1 hour instead of at higher temperatures (Fig. 2d). In addition, the XRD spectrum of CS-Te NPs (200°C) showed peaks corresponding to the crystalline phases (001), (100), (101), (102), (110), (111), (003), (201), (112), (110), (113), and (211) at 15.73°, 23.07°, 27.50°, 38.25°, 40.47°, 43.28°, 45.94°, 49.60°, 51.31°, 56.95°, 62.84°, and 65.91°. These crystalline characteristics mostly belong to Te and are consistent with the standard Te hexagonal / triangular structure (JCPDS No. 36-1452). Furthermore, CS-Te preparation significantly reduced the amorphous crystal peaks of chitosan. Therefore, these results indicate that Te NPs fabricated with CS were successfully synthesized without additional reducing agents.

[0109] 3.2.5. XPS analyze

[0110] The elemental composition of CS-Te NPs was studied through XPS analysis. The investigation spectrum of CS-Te NPs is evidenced by the presence of Te, O, N, and C (Fig. 3a). Among them, Te3d exhibited peaks of higher intensity and area. Additionally, Fig. 3b shows Te3d5, respectively. / 2 and Te3d3 / 2 It exhibits two characteristic peaks corresponding to 576.29 eV and 586.14 eV. Similarly, cobalt telluride nanorods show Te3d5 at 572 eV and 586 eV, respectively. / 2 and Te3d3 / 2 It has been reported that peaks were exhibited. Furthermore, Fig. 3c shows O1 at 531.08 eV. Fig. 3d shows N1 at 399.08 eV. Fig. 3e shows C1 at 285.46 eV. Additionally, the atomic (%) of Te3d, O1s, C1s, N1s, and K2p were confirmed to be 6.68%, 24.79%, 51.58%, 14.41%, and 2.54%, respectively. Interestingly, almost no K2p content was observed in the spectrum of the CS-Te NPs, which is due to the use of potassium tellurite salt as a precursor salt. Since the CS-Te NPs were prepared by an in situ synthesis method, reduced potassium ions could be bound to the CS surface. The FWHM (full-length strength at half maximum) intensities of Te3d, O1s, C1s, N1s, and K2p were measured at 2.76 ev, 3.37 ev, 3.4 ev, 3.75 ev, and 2.45 ev, respectively. These results demonstrated that Te NPs were successfully fabricated with CS.

[0111] 3.2.6. thermal weight analyze( TGA )

[0112] The thermal stability of CS and CS-Te NPs was determined between 10°C and 1000°C by TGA analysis and is shown in Fig. 4. The TGA curve of CS indicates two main decomposition stages, namely the initial decomposition stage. Due to the evaporation of adsorbed and hydrogen-bonded water molecules, a weight loss of 8.947% occurred between 20°C and 253°C. The second stage of CS showed a weight loss of 66.46% between 254°C and 1000°C (Fig. 4), which may be due to the depolymerization and decomposition of organic molecules through the dissociation of glycosidic bonds. In the case of CS-Te NPs, thermal decomposition occurred in four stages. In the first stage of decomposition, CS-Te NPs observed a weight loss of 4.569% between 10°C and 250°C due to a smaller loss of water content compared to CS alone. The second stage of weight loss for CS-Te NPs was 34.81% between 252°C and 420°C due to the dissociation of CS. The third stage showed a maximum weight loss (56.95%) of CS-Te NPs during the 430–830°C period due to the decomposition of CS and Te. In the fourth stage, a minimum weight loss (2.97%) was observed due to the maximum decomposition of CS and Te. The CS-Te combination improved thermal stability compared to CS alone. Similarly, Fe3O4 nanoparticles improved the thermal stability of CS-based films, whereas CS-based films with metal particles exhibited low thermal stability.

[0114] 3.3. CS - Te Biological applications of NP

[0115] 3.3.1. Antimicrobial Activity

[0116] The bacterial growth inhibitory ability of CS-Te NPs was evaluated against pathogenic bacteria using the well-diffusion method (Fig. 5a). Briefly, the antimicrobial activity of CS-Te NPs at various concentrations (20 μg, 30 μg, 40 μg, and 50 μg) was compared with the standard antibiotic TCH (20 μg). The results indicate that CS-Te NPs significantly inhibit the growth of both Gram-positive (S. aureus, B. cereus, and L. monocytogenes) and Gram-negative (E. coli and S. enterica) bacteria. Furthermore, the bacterial inhibitory properties of CS-Te NPs vary significantly depending on the concentration. Additionally, CS-Te NPs significantly inhibit bacterial growth in the order of E. coli, S. enterica, S. aureus, B. cereus, and L. monocytogenes. These results indicate that CS-Te NPs can inhibit Gram-negative bacteria more effectively than Gram-positive bacteria. This is due to the positive surface properties of CS-Te NPs that can interact with Gram-negative bacterial cells (as demonstrated by zeta potential analysis). Lower concentrations of CS-Te NPs (20 μg) showed inhibition zones of 14.5±0.5 mm for B. cereus, 30.5±0.5 mm for S. aureus, 5.0±0.0 mm and 32.1±0.9 mm for L. monocytogenes, and 31.0±1.0 mm for E. coli and S. enterica (Table 1).

[0117] Table 1 is a table regarding the antimicrobial activity of CS-Te NPs, specifically the inhibition zone (mm) of CS-Te NPs against various pathogenic bacterial strains. In Table 1 below, TCH is tetracycline hydrochloride used as a control group.

[0118] Sample Concentration (㎍) Zone of inhibition (mm) B. cereus S. aureus L. monocytogenes E. coli S. enterica CS-Te NPs 20 14.5±0.5 30.5±0.5 5.0±0.0 32.1±0.9 31.0±1.0 30 16.0±0.5 32.8±1.3 5.0±0.0 33.6±0.4 32.1±0.9 40 17.1±0.4 33.6±0.4 5.0±0.0 34.6±0.3 32.8±0.8 50 18.1±0.4 33.8±0.3 5.0±0.0 36.3±0.2 34.1±0.4 TCH 20 20.0±0.5 20.8±0.7 20.4±0.5 21.5±0.5 19.8±0.7

[0119] Similarly, TCH (20 μg) measured 20.1 ± 0.5 mm for B. cereus, 20.8 ± 0.7 mm for S. aureus, 20.4 ± 0.5 mm for L. monocytogenes, 21.5 ± 0.5 mm for E. coli, and 19.8 ± 0.7 mm for S. Enterica, while CS-Te NPs exhibited superior antibacterial activity against E. coli, S. entrica, and S. aureus compared to TCH.

[0120] In addition, bacterial growth kinetics for growth media containing various concentrations of CS-Te NPs were investigated for 48 hours using a UV-visible spectrophotometer (Fig. 5b-f). The results showed that CS-Te NPs significantly inhibited the growth of S. aureus and E. coli at low concentrations (0.95–1.9 μg / mL). For B. cereus, L. monocytogenes, and E. coli, low concentrations of CS-Te NPs could initially inhibit growth, but this could not be sustained due to bacterial resistance. Furthermore, CS-Te NPs exhibited MICs of 125 μg / mL, 125 μg / mL, 0.95 μg / mL, 62.5 μg / mL, and 1.9 μg / mL for B. cereus, L. monocytogenes, S. aureus, S. enterica, and E. coli, respectively. In addition, the antibiole activity of CS-Te NPs at various concentrations against the bacterial pathogens mentioned in this study was investigated (Figure 6). The results showed that B. cereus and S. aureus formed strong biofilms at lower concentrations of CS-Te NPs, and that these biofilms could be eradicated at higher concentrations. Furthermore, L. monocytogenes failed to form strong biofilms even at lower concentrations of CS-Te NPs. For Gram-negative bacteria, biofilm formation was significantly reduced as the concentration of CS-Te NPs decreased. Biofilm inhibition IC of CS-Te NPs50 The concentrations were 7.09 μg / mL, 125 μg / mL, 25.44 μg / mL, 2.78 μg / mL, and 0.95 μg / mL for B. cereus, L. monocytogenes, S. aureus, S. Enterica, and E. coli, respectively.

[0121] 3.3.2. CS - Te Antifungal activity of NP

[0122] The antifungal properties of CS-Te NPs were evaluated against filamentous and non-filamentous fungi (Fig. 7). As a result, compared to the standard antifungal agent fluconazole, it exhibited higher antifungal activity against A. flavus, A. fumigatus, and C. albicans in terms of ZOI (Table 2). This antifungal activity is positively dependent on the concentration of CS-Te NPs. However, while low concentrations of CS-Te NPs failed to inhibit A. niger, high concentrations demonstrated inhibitory ability. Additionally, filamentous fungal cells were cultured with various concentrations of CS-Te NPs for 6 hours to evaluate their inhibitory properties. The results showed that increasing the concentration of CS-Te NPs substantially inhibited fungal growth, as rapid growth of each fungus was observed (Fig. 11).

[0123] 3.3.3. Antioxidant Activity

[0124] The antioxidant properties of CS-Te NPs at various concentrations were evaluated by determining DPPH and ABTS radical scavenging abilities (Fig. 7b-c). The results showed that CS-Te NPs exhibited higher ABTS radical scavenging ability than DPPH radical scavenging ability. The radical scavenging ability of CS-Te NPs varied significantly with concentration. However, no difference in radical scavenging ability was observed at the maximum concentration of CS-Te NPs. Furthermore, CS-Te NPs showed IC50s of 250 μg / mL and 125 μg / mL for DPPH and ABTS radicals, respectively. 50The concentrations were shown (Fig. 7b-c). Fungal-synthesized Te NPs had IC50 50 This demonstrated higher DPPH radical scavenging activity at 20.66 μg / mL. Release behavior may vary depending on the pH environment.

[0125] 3.3.4. Cytotoxicity Analysis

[0126] The cytotoxic properties of CS-Te NPs were evaluated in normal cells (NIH3T3 cells) and cancer cell lines (A549 and PC3 cells). Figure 8a shows the cell viability of CS-Te NPs at serially diluted concentrations in NIH3T3 cells. The results indicate that 25 μg / mL of CS-Te NPs did not reduce NIH3T3 cell growth by less than 80%. However, as the concentration of CS-Te NPs (50 μg / mL) increased, it affected NIH3T3 cell growth by more than 50%. Interestingly, 25 μg / mL of CS-Te NPs reduced the cell viability of A549 cells by more than 50%. The same cellular effect was observed in PC3 cells when treated. This study reports that Te NPs possess potential anticancer activity due to their cellular antioxidant capacity, demonstrated by the scavenging of reactive oxygen species (ROS). IC of CS-Te NPs 50 The concentrations were 42.1±2.44 μg / mL, 23.6±1.85 μg / mL, and 33.5±2.76 μg / mL for NIH3T3, A549, and PC3 cells, respectively. The results indicate that CS-Te NPs significantly inhibit the growth of A549 cells more than PC3 cells. In addition, fluorescence staining analysis was performed to understand the anticancer mechanism of CS-Te NPs in A549 and PC3 cells. The AO / EB staining analysis in Figure 8c showed IC50 compared to the control group (green cells). 50Treatment with high concentrations of CS-Te NPs showed apoptosis (cells stained yellow). Furthermore, CS-Te NP treatment induced nuclear damage (erythrocytes stained with PI), loss of mitochondrial membrane potential (decrease in erythrocyte intensity), and induction of reactive oxygen species (ROS) production (green cells stained with DCFH-DA) in A549 cells compared to control cells. A similar pattern was observed in PC3 cells when treated with CS-Te NPs. However, AO / EB staining showed that treatment with CS-Te NPs induced apoptosis and necrotic apoptosis in PC3 cells. These results indicate that low concentrations of CS-Te NPs cause severe toxicity to cancer cells (A549 and PC3 cells), whereas they do not exhibit severe toxicity to normal cells (NIH3T3 cells).

[0128] 4. Conclusion

[0129] In this study, CS-based Te NPs were successfully synthesized via an in situ synthesis method for advanced antimicrobial, antioxidant, and anticancer applications, along with cell compatibility. The morphological and chemical properties of the NPs were characterized by TEM, XRD, FTIR, zeta potential, and TGA. This study revealed that CS enables the synthesis of Te NPs without the aid of additional reducing agents or stabilizers. TEM analysis demonstrated Te NPs capped by CS, and aggregated particles appeared as Te NPs dispersed within the CS matrix. Furthermore, elemental analysis confirmed the presence of Te, N, C, and K. Additionally, CS-Te NPs exhibited superior thermal stability at higher temperatures compared to pure CS. Regarding biological applications, CS-Te NPs demonstrated potent antimicrobial activity against bacteria, fungi, and yeasts. In particular, CS-Te NPs exhibited stable and high antimicrobial activity against Gram-negative bacteria. Moreover, CS-Te NPs successfully inhibit the formation of both Gram-positive and Gram-negative biofilms. Subsequently, potent antioxidant activity against DPPH and ABTS free radicals was observed. In addition, CS-Te NPs at low concentrations are highly toxic to cancer cells compared to normal cells. Therefore, the present invention concludes that CS-Te NPs can be an important multifunctional material for biomedical applications. Accordingly, the present invention specifies that it has developed chitosan tellurium nanoparticles and a method for manufacturing the same, as novel nanoparticles formed by combining chitosan and tellurium, which are manufactured into nanostructures using chitosan.

[0131] Although the present invention has been described together with the accompanying drawings, this is merely one example among various embodiments containing the gist of the invention, and its purpose is to enable those skilled in the art to easily implement it; it is clear that the present invention is not limited to the embodiments described above. Accordingly, the scope of protection of the present invention should be interpreted by the claims below, and all technical ideas within an equivalent scope by modification, substitution, replacement, etc., without departing from the gist of the invention shall be included within the rights of the present invention. Furthermore, it is clarified that some components in the drawings are provided in an exaggerated or reduced size compared to the actual form to more clearly explain the configuration. Explanation of the symbols

[0132] (S10): Potassium tellurite solution preparation step (S20): Chitosan solution preparation step (S30): Mixing step (S40): Precipitation formation stage (S50): Collection stage (S60): Freeze-drying step

Claims

Claim 1 A potassium tellurite solution preparation step (S10) for preparing a potassium tellurite solution by dissolving potassium tellurite (K2TeO3) in distilled water; a chitosan solution preparation step (S20) for preparing a chitosan solution by dissolving low molecular weight chitosan with a molecular weight of 50-190 kDa in an acetic acid solution; a mixing step (S30) for preparing a mixture by adding the chitosan solution prepared in the chitosan solution preparation step (S20) to the potassium tellurite solution prepared in the potassium tellurite solution preparation step (S10); a precipitate formation step (S40) for forming a precipitate by stirring the mixture from the mixing step (S30); and a collection step (S50) for collecting chitosan tellurium nanoparticles (CS-Te NPs) by centrifuging the precipitate formed in the precipitate formation step (S40). A method for manufacturing chitosan tellurium nanoparticles, characterized by including a freeze-drying step (S60) in which the chitosan tellurium nanoparticles (CS-Te NPs) collected in the collection step (S50) are washed with distilled water and freeze-dried. Claim 2 A method for manufacturing chitosan tellurium nanoparticles according to claim 1, wherein the potassium tellurium solution in the potassium tellurium solution manufacturing step (S10) is prepared by dissolving potassium tellurium (K2TeO3; MW 253.79 g / mol) in distilled water to a concentration of 10 mM. Claim 3 delete Claim 4 A method for manufacturing chitosan tellurium nanoparticles according to claim 1, wherein the mixture in the mixing step (S30) is prepared by adding the chitosan solution prepared in the chitosan solution preparation step (S20) to the potassium tellurium solution prepared in the potassium tellurium solution preparation step (S10) in a volume ratio of 1000:

200. Claim 5 A method for manufacturing chitosan tellurium nanoparticles according to claim 1, wherein the precipitate in the precipitate formation step (S40) is formed by stirring the mixture of the mixing step (S30) at a temperature of 5 to 45°C for 20 to 40 minutes. Claim 6 A method for manufacturing chitosan tellurium nanoparticles according to claim 1, wherein the chitosan tellurium nanoparticles (CS-Te NPs) in the collection step (S50) are collected by centrifuging the precipitate formed in the precipitate formation step (S40) at a speed of 10,000 to 14,000 rpm for 10 to 20 minutes. Claim 7 Chitosan tellurium nanoparticles (CS-Te NPs) characterized by centrifuging and collecting the precipitate formed by stirring a mixture prepared by adding a chitosan solution prepared by dissolving low molecular weight chitosan with a molecular weight of 50-190 kDa in an acetic acid solution to a potassium tellurite solution prepared by dissolving potassium tellurite (K2TeO3) in distilled water, washing with distilled water, and freeze-drying with distilled water. Claim 8 Chitosan tellurium nanoparticles (CS-Te NPs) according to claim 7, wherein the potassium tellurite solution is prepared by dissolving potassium tellurite (K2TeO3; MW 253.79 g / mol) in distilled water to a concentration of 10 mM. Claim 9 delete Claim 10 Chitosan tellurium nanoparticles (CS-Te NPs) according to claim 7, characterized in that the mixture is prepared by adding a chitosan solution to the potassium tellurite solution in a volume ratio of 1000:

200. Claim 11 Chitosan tellurium nanoparticles (CS-Te NPs) according to claim 7, characterized in that the precipitate is formed by stirring the mixture at a temperature of 5 to 45°C for 20 to 40 minutes. Claim 12 In claim 7, the chitosan tellurium nanoparticles (CS-Te NPs) are characterized by collecting the precipitate by centrifuging it at a speed of 10,000 to 14,000 rpm for 10 to 20 minutes.

Citation Information

Patent Citations

  • Pharmaceutical composition for acute lymphoblastic leukemia comprising zinc-chitosan nanoparticles

    KR1020190111324A

  • Rutin-mediated palladium nanoclusters encapsulated with folic acid-conjugated chitosan and method for preparing the same

    KR1020230072779A